These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 17993811)

  • 1. New targets and emerging therapies for reducing LDL cholesterol.
    Lilly SM; Rader DJ
    Curr Opin Lipidol; 2007 Dec; 18(6):650-5. PubMed ID: 17993811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel therapies and new targets of treatment for familial hypercholesterolemia.
    Goldberg AC
    J Clin Lipidol; 2010; 4(5):350-6. PubMed ID: 21122677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect?
    Sahebkar A; Watts GF
    Cardiovasc Drugs Ther; 2013 Dec; 27(6):559-67. PubMed ID: 23913122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-density lipoprotein cholesterol lowering therapies: what is on the horizon?
    Gadi R; Figueredo VM
    J Cardiovasc Med (Hagerstown); 2015 Jan; 16(1):1-10. PubMed ID: 25379719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel nonstatin strategies to lower low-density lipoprotein cholesterol.
    Davidson MH
    Curr Atheroscler Rep; 2009 Jan; 11(1):67-70. PubMed ID: 19080731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel therapeutic agents for lowering low density lipoprotein cholesterol.
    Joy TR
    Pharmacol Ther; 2012 Jul; 135(1):31-43. PubMed ID: 22465160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Other therapies for reducing low-density lipoprotein cholesterol: medications in development.
    Stein EA
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):99-119. PubMed ID: 19217514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ebbs and flows in the development of cholesterol-lowering drugs: prospects for the future.
    Hajhosseiny R; Sabir I; Khavandi K; Wierzbicki AS
    Clin Pharmacol Ther; 2014 Jul; 96(1):64-73. PubMed ID: 24699033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New and Emerging LDL Cholesterol-Lowering Drugs.
    Kosmas CE; Frishman WH
    Am J Ther; 2015; 22(3):234-41. PubMed ID: 25486520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-density lipoprotein cholesterol reduction by inhibition of PCSK9.
    Stein EA
    Curr Opin Lipidol; 2013 Dec; 24(6):510-7. PubMed ID: 24184943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homozygous autosomal dominant hypercholesterolaemia: prevalence, diagnosis, and current and future treatment perspectives.
    Sjouke B; Hovingh GK; Kastelein JJ; Stefanutti C
    Curr Opin Lipidol; 2015 Jun; 26(3):200-9. PubMed ID: 25950706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apolipoprotein B antisense inhibition--update on mipomersen.
    Gebhard C; Huard G; Kritikou EA; Tardif JC
    Curr Pharm Des; 2013; 19(17):3132-42. PubMed ID: 23317401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular risk reduction: the future of cholesterol lowering drugs.
    Bou Malham S; Goldberg AC
    Curr Opin Pharmacol; 2016 Apr; 27():62-9. PubMed ID: 26939026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microsomal transfer protein inhibition in humans.
    Cuchel M; Rader DJ
    Curr Opin Lipidol; 2013 Jun; 24(3):246-50. PubMed ID: 23594709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human cholesterol metabolism and therapeutic molecules.
    Charlton-Menys V; Durrington PN
    Exp Physiol; 2008 Jan; 93(1):27-42. PubMed ID: 18165431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Squalene synthase inhibitors : clinical pharmacology and cholesterol-lowering potential.
    Charlton-Menys V; Durrington PN
    Drugs; 2007; 67(1):11-6. PubMed ID: 17209661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel LDL-oriented pharmacotherapeutical strategies.
    Huang LZ; Zhu HB
    Pharmacol Res; 2012 Apr; 65(4):402-10. PubMed ID: 22306845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular biology of PCSK9: its role in LDL metabolism.
    Horton JD; Cohen JC; Hobbs HH
    Trends Biochem Sci; 2007 Feb; 32(2):71-7. PubMed ID: 17215125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proprotein convertase subtilisin/kexin type 9, its variants and regulation of low-density lipoprotein cholesterol.
    Wierzbicki AS
    Curr Opin Lipidol; 2007 Apr; 18(2):227-9. PubMed ID: 17353672
    [No Abstract]   [Full Text] [Related]  

  • 20. Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo.
    Schmidt RJ; Beyer TP; Bensch WR; Qian YW; Lin A; Kowala M; Alborn WE; Konrad RJ; Cao G
    Biochem Biophys Res Commun; 2008 Jun; 370(4):634-40. PubMed ID: 18406350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.